Recent findings from a phase 1b/II study, involving 52 treatment-naïve AML patients with adverse cytogenetic and molecular aberrations (complex cytogenetics and TP53-mutated AML), that were given Magrolimab in combination with azacytidine (AZA), showed that almost half of TP53-mutant AML patients achieved complete remission, and a median OS of 12.9 months (Sallman et al., 2020). The gene discussed is TP53; the disease is acute myeloid leukemia.